Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NQ:AMRX)

7.750 -0.210 (-2.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga
3 of Wall Street’s Favorite Stocks in the Doghouse
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Intellectual Property
Exposures Intellectual Property
Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory
The observance of black spots was reported in a product quality complaint, the U.S. FDA said, while noting that oral products contaminated with Aspergillus may result in serious and life-threatening... 
Via Stocktwits
Topics Artificial Intelligence Product Recall
Exposures Artificial Intelligence Legal Product Safety
Amneal to Participate at Upcoming Investor Conferences in June
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
Amneal Gets FDA Nod For Self-Administrable Migraine Injection
The company said the injection is the first and only dihydroergotamine (DHE) autoinjector for treating migraine and cluster headaches. 
Via Stocktwits
Topics Data Breach
Exposures Information Security Product Safety
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Russell 2000 Stocks in Hot Water
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
From Amneal Pharmaceuticals LLC
Via GlobeNewswire
3 Value Stocks in Hot Water
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
3 Small-Cap Stocks Facing Headwinds
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed
Amneal Pharmaceuticals reported first-quarter 2025 adjusted earnings per share of 21 cents, up from 14 cents a year ago. 
Via Benzinga
Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3%
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 5.5% year on year to $695.4 million. On the other hand, the company’s... 
Via StockStory
Amneal Reports First Quarter 2025 Financial Results
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 2, 2025
Via Benzinga
Examining the Future: Amneal Pharmaceuticals's Earnings Outlook
Via Benzinga
Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
3 Profitable Stocks Skating on Thin Ice
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
2 Reasons to Avoid AMRX and 1 Stock to Buy Instead
Over the past six months, Amneal’s shares (currently trading at $6.85) have posted a disappointing 17.6% loss while the S&P 500 was down 8.1%. This might have investors contemplating their next move. 
Via StockStory
Topics Economy Government Stocks
Exposures Economy Political Tariff
3 of Wall Street’s Favorite Stocks That Concern Us
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal to Report First Quarter 2025 Results on May 2, 2025
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients
Amneal shares data showing Crexont improves sleep and motor symptoms in Parkinson's patients, with Phase 4 trial underway for further evaluation. 
Via Benzinga
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
From Amneal Pharmaceuticals, Inc.
Via Business Wire
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Amneal to Participate at Upcoming Investor Conference
From Amneal Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.